Patient characteristics, phase 2
| Patient characteristics . | Donors . | Recipients . |
|---|---|---|
| Number | 34 | 33 |
| Median age, d (range) | 50 (28-65) | 54 (26-68) |
| Male, % | 53 | 65 |
| Mean weight, kg (range) | 95 (54-172) | 92 (61-183) |
| Mean apheresis volume, L (range) | 17.9 (3.7-20) | NA |
| Diagnosis (n) | NA | AML (14) |
| NHL (9) | ||
| CLL (3) | ||
| MDS (3) | ||
| ALL (3) | ||
| CML (1) | ||
| HD (1) | ||
| Refractory/persistent disease, % (n) | NA | 48.5 (16) |
| Conditioning regimen, % (n) | NA | Myeloablative: 85 (28) |
| Fludarabine RIC: 15 (5) | ||
| Median follow up, d (range) | 27-35 | 248 (37-695) |
| CMV at risk, % | 62 | |
| Patient characteristics . | Donors . | Recipients . |
|---|---|---|
| Number | 34 | 33 |
| Median age, d (range) | 50 (28-65) | 54 (26-68) |
| Male, % | 53 | 65 |
| Mean weight, kg (range) | 95 (54-172) | 92 (61-183) |
| Mean apheresis volume, L (range) | 17.9 (3.7-20) | NA |
| Diagnosis (n) | NA | AML (14) |
| NHL (9) | ||
| CLL (3) | ||
| MDS (3) | ||
| ALL (3) | ||
| CML (1) | ||
| HD (1) | ||
| Refractory/persistent disease, % (n) | NA | 48.5 (16) |
| Conditioning regimen, % (n) | NA | Myeloablative: 85 (28) |
| Fludarabine RIC: 15 (5) | ||
| Median follow up, d (range) | 27-35 | 248 (37-695) |
| CMV at risk, % | 62 | |
CMV at risk is defined as CMV seropositive donor, recipient, or both.
AML, acute myeloid lymphoma; CLL, chronic lymphocytic leukemia; CML, chronic myeloid lymphoma; HD, Hodgkin disease; MDS, myelodysplastic syndrome; NA, nonapplicable; NHL, non-Hodgkin lymphoma.